Cytomegalovirus (CMV) esophagitis is well-documented in immunocompromised patients. A few studies have described CMV infection in immunocompetent patients diagnosed with a critical illness. However, CMV esophagitis has rarely been documented in immunocompetent hosts. We report a case of CMV esophagitis in an immunocompetent patient who presented with chest pain and dysphagia that was successfully resolved with ganciclovir treatment. Our case supports observations that CMV esophagitis can cause significant morbidity, regardless of immune system status. Keywords: Cytomegalovirus, esophagus, immunocompetent INTRODUCTION Cytomegalovirus (CMV) is a type of herpesvirus and a common viral pathogen in humans. CMV causes various diseases, such as retinitis, hepatitis, encephalitis, pneumonia, and gastrointestinal infection in immunocompromised patients (1,2). CMV-associated gastrointestinal infection has been reported to mainly invade the colon and stomach, but it may also occur in other organs (2).CMV-associated gastrointestinal infections are generally resolved without clinical symptoms in immunocompetent patients, but the infection can be fatal in the immunocompromised (3).
INTRODUCTION
Cytomegalovirus (CMV) is a type of herpesvirus and a common viral pathogen in humans. CMV causes various diseases, such as retinitis, hepatitis, encephalitis, pneumonia, and gastrointestinal infection in immunocompromised patients (1, 2) . CMV-associated gastrointestinal infection has been reported to mainly invade the colon and stomach, but it may also occur in other organs (2) .CMV-associated gastrointestinal infections are generally resolved without clinical symptoms in immunocompetent patients, but the infection can be fatal in the immunocompromised (3).
There is now growing evidence of CMV infection in immunocompetent patients (3) (4) (5) . Here, we present a case of CMV esophagitis in an immunocompetent patient, who presented with severe progressive chest pain and dysphagia after severe post-operative ileus (POI). The patient was successfully treated with ganciclovir. This positive outcome has been added to an updated review of the literature regarding CMV esophagitis in immunocompetent hosts.
CASE PRESENTATION
A 67-year-old male patient was referred to the gastroenterology department following 3 days of progressive chest pain and dysphagia. The chest pain was localized to the retrosternum and was aggravated by eating. His dysphagia was localized to the retrosternum and neck with associated odynophagia. Ten days before the attack of chest pain and dysphagia, the patient has undergone surgery for a burst fracture of the 12 th thoracic vertebra and left orbital bone fracture caused by a traffic accident. Two days after surgery, he developed abdominal distension, nausea and vomiting. He continued to vomit, and subsequently developed aspiration pneumonitis. He was managed medically for aspiration pneumonitis and POI, and his symptoms subsequently improved.
At time of referral, the patient's vital signs were stable with blood pressure, 130/80 mmHg; heart rate, 72 beats/ min; respiration rate, 18/min; and body temperature, 37°C. The physical examination revealed a chronically ill-looking man with mild epigastric tenderness. The complete blood count showed leukocytes, 8,200/μL; hemoglobin, 9.8 g/dL; and platelet count, 414,000/μL. Blood chemistry showed sodium, 137 mmol/L; potassium, 3.5 mmol/L; chloride, 101 mmol/L; aspartate aminotransferase/alanine aminotransferase, 58/34 IU/L; blood urea nitrogen, 14 mg/dL; creatinine, 0.44 mg/dL; albumin, 3.1 g/dL; and C-reactive protein, 6.08 mg/dL. The patient was negative for HBs antigen, anti-HCV antibody, and anti-HIV antibody. The patient had taken medications to treat hypertension, diabetes mellitus, and chronic obstructive pulmonary disease for two years. He declined a blood transfusion and immunosuppressant drugs, such as glucocorticoids.
Case Report
Upon referral, the patient underwent esophagogastroduodenoscopy (EGD), which revealed a patch distribution of superficial ulcers on the larynx, the upper and the mid esophagus ( Figure 1a ). In addition, confluent superficial ulcers were observed in the lower esophagus ( Figure 1b) . Based on the patient's recent history of vomiting associated with POI, secondary reflux esophagitis was initially considered in the differential diagnosis. However, the presence of a systemic esophagitis disease such as CMV esophagitis could not be excluded with certainty due to the presence of multiple discrete ulcers on the larynx. Thus, we performed a biopsy of the lower esophagus and performed polymerase chain reaction (PCR) for the presence of CMV in the tissue. Serum culture of CMV, antibody tests for CMV IgM and IgG, real-time PCR for CMV, and an antigenemia test for CMV were also conducted. Pathological examination of the esophageal biopsy specimens showed an ulcerated esophageal mucosa with acute inflammation and intranuclear and intracytoplasmic inclusion bodies (Figure 2a ). Immunostaining using a specific anti-CMV antibody was positive (Figure 2b) , as was CMV PCR of the esophageal tissue. Serologic tests showed that the patient was positive for CMV IgG, negative for CMV IgM, and negative for CMV antigenemia.
Initial therapy began with administration of a proton-pump inhibitor. However, chest pain and dysphagia did not improve after 7 days of therapy. Therefore, ganciclovir (5 mg/kg) was administered intravenously at 12-h intervals for 14 days. This treatment was well-tolerated and the symptoms completely resolved. A follow-up EGD revealed healing of the superficial ulcers on the larynx (Figure 3a ) and the esophagus (Figure 3b ). The informed consent was taken from patient for this case presentation.
DISCUSSION
There have been few studies describing CMV infection in immunocompetent patients (3) (4) (5) , which is generally asymptomatic or may present as a form of mononucleosis syndrome. However, CMV infection is associated with prolonged hospitalization or death in immunocompetent patients with critical illnesses. To-date, organ-specific complications have been described in immunocompetent hosts. Gastrointestinal involvement with CMV infection is uncommon in immunocompetent hosts, with cases primarily limited to reports of CMV colitis (6). In contrast, little is known about CMV esophagitis in immunocompetent patients.
A PubMed search (www.ncbi.nlm.nih.gov/PubMed) and KoreaMed search (http://www.koreamed.org/SearchBasic.php) using a combination of terms including 'cytomegalovirus/CMV' , 'esophagitis/esophageal ulcer' and 'immunocompetence/immunocompetent' yielded nine articles (7) (8) (9) (10) (11) (12) (13) (14) (15) . Table 1 summarizes the clinical features of these nine cases of CMV esophagitis in immunocompetent patients and includes data from our current patient, bringing the total to 10 reported cases. CMV esophagitis in immunocompetent hosts occurs more frequently in males, with a median age of 56.8 years. Advancing age is potential risk factor for CMV esophagitis in immunocompetent hosts, which is likely a reflection of a weakened immune system as a consequence of aging (16) . There are extensive studies demonstrating that aging is associated with a decline in cellular and humoral immunity.Age-related dysfunctions of B and T cell lymphocytes, and age-related impairments in the regulation of the immune response by cytokines and other factors, and perturbation of mucosal immunity are thought to contribute to a relative immunodeficiency in the elderly. Co- morbid diseases are also more common in geriatric patients that in younger patients. Reactivation has been presumed to be a consequence of the severity of immune system compromise during critical illness, the intrinsic viral load, and perhaps the severity of the reactivation stimulus (17) . Thus, critical illness is another potential risk factor of CMV esophagitis in immunocompetent patients. Our review of the literature found seven patients with critical illnesses, including brain hemorrhage, abdominal surgery and infections, and pulmonary infections. Two patients were alcoholics, and only one had no medical problems before the CMV esophagitis diagnosis. The role of CMV infection in immunocompetent patients with critical illness has been investigated previously (5) . Although these studies used various virologic and statistical methods and designs, most demonstrated that CMV infection is common in critically ill patients and is associated with one or more adverse clinical outcomes (5).
In our review of the literature, the common symptoms of CMV esophagitis were bleeding, epigastric pain and dysphagia. Although previous reports suggested that gastrointestinal hemorrhage caused by CMV esophagitis is rare, bleeding was a common symptom of CMV esophagitis in immunocompetent patients in our case review (18) . Co-infection of other organs, including the larynx, stomach, duodenum, and colon, was observed in almost half of the reported patients.
Endoscopic findings of CMV esophagitis in immunocompetent patients include deep ulcers, superficial ulcers and erosions. EGD revealed a variety of findings, such as mucosal ulcerations, erosions, hemorrhage and nodules, in CMV esophagitis of immunocompromised patients. In transplant cases, erosions or ulcers progress and fuse together, thereby forming a giant or geographic ulcer (19) . Because the endoscopic appearance is nonspecific, the diagnosis rests on the histopathologic identification of viral-infected cells in biopsy tissues, occasionally supplemented by ancillary techniques such as immunohistochemistry or in situ hybridization (20) .
Ganciclovir was required for treatment in 80% of immunocompetent patients with CMV esophagitis, with the minority of patients managed conservatively. In our case, the patient did not response to proton-pump inhibitor treatment, and symptoms eventually resolved only after ganciclovir treatment. To-date, CMV treatment has not been established in immunocompetent patients, although it is well-established in the immunocompromised. Since the majority of immunocompetent patients with CMV disease recover without intervention, it is difficult to determine whether or not antiviral therapy has a significant impact on clinical outcome.
In conclusion, we have described our observations of one immunocompetent patient with CMV esophagitis and have reviewed nine previously reported cases. This information indicates that CMV esophagitis can cause significant morbidity, even in immunocompetent patients, and support conducting large studies to determine the clinical usefulness of ganciclovir treatment. 
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